Assessment and prognostic impact of a new classification using HER2 and HER3 status in resected gastric cancer in a european cohort.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.4_suppl.65
Abstract: 65Background: HER2 status is a predictive biomarker to response to trastuzumab in metastatic gastric adenocarcinomas. However, relatively little is known about the role of HER2 and HER3 in the non-metastatic disease in European population. Methods:… read more here.
Keywords: her2; her3 status; expression; her2 her3 ... See more keywords